Early Herceptin Use a Breast Cancer Breakthrough

Last month, the National Cancer Institute announced that the drug cuts recurrences in half when given with chemotherapy to women with early-stage disease. On Monday, researchers released more details of their findings to thunderous applause from thousands of cancer specialists attending the annual meeting of the American Society of Clinical Oncology, held in Orlando. "The results were spectacular," said Len Lichtenfeld, MD, deputy chief medical officer of the American Cancer Society. "I don't think anyone left the room with any doubt this is the new standard of care."

Yahoo! Health News: Early Herceptin Use a Breast Cancer Breakthrough

BioBOOM Op/ED: This is a huge win for biotech and Genetech in particular. After the recent poor press for the Vioxx and Tysabri disaster, we may see a more positive shift in both public attitude and money flow towards the industry if this kind of news and DATA keeps coming.

No comments:

Blog Archive